Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-04-07
2011-10-11
Lewis, Patrick (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
08034796
ABSTRACT:
Mutual prodrugs of glucosamine, and derivatives and analogs of glucosamine and an anti-inflammatory agent, compositions thereof, and methods for, e.g., treating disorders and conditions by administration of the compositions are provided. Topical compositions of glucosamine, and derivatives and analogs of glucosamine are also provided.
REFERENCES:
patent: 4278679 (1981-07-01), Madison et al.
patent: 4855090 (1989-08-01), Wallach
patent: 4911928 (1990-03-01), Wallach
patent: 4917951 (1990-04-01), Wallach
patent: 4942038 (1990-07-01), Wallach
patent: 5000960 (1991-03-01), Wallach
patent: 5032457 (1991-07-01), Wallach
patent: 5104736 (1992-04-01), Wallach
patent: 5147723 (1992-09-01), Wallach
patent: 5219538 (1993-06-01), Henderson et al.
patent: 5234767 (1993-08-01), Wallach
patent: 5474848 (1995-12-01), Wallach
patent: 5628936 (1997-05-01), Wallach
patent: 5703119 (1997-12-01), Baragi et al.
patent: 6083996 (2000-07-01), Büyüktimkin et al.
patent: 6133230 (2000-10-01), Anastassiades
patent: 6299902 (2001-10-01), Jun et al.
patent: 6346519 (2002-02-01), Petrus
patent: 6355666 (2002-03-01), Lai et al.
patent: 6368618 (2002-04-01), Jun et al.
patent: 6429223 (2002-08-01), Lai et al.
patent: 6479469 (2002-11-01), Anastassiades
patent: 6579543 (2003-06-01), McClung
patent: 6656925 (2003-12-01), Petrus
patent: 6677321 (2004-01-01), Levin
patent: 6685928 (2004-02-01), Uhrich et al.
patent: 6809111 (2004-10-01), Carter
patent: 6846818 (2005-01-01), DeMello et al.
patent: 7112578 (2006-09-01), Levin
patent: 2002/0022052 (2002-02-01), Dransfield
patent: 2002/0045597 (2002-04-01), Anastassiades
patent: 2002/0106345 (2002-08-01), Uhrich et al.
patent: 2002/0119952 (2002-08-01), Petrus
patent: 2003/0114416 (2003-06-01), Pulaski et al.
patent: 2003/0114418 (2003-06-01), Pulaski et al.
patent: 2003/0125303 (2003-07-01), Kucharchuk
patent: 2004/0038948 (2004-02-01), Uhrich
patent: 2004/0147445 (2004-07-01), Levin
patent: 2004/0152665 (2004-08-01), Anastassiades
patent: 2004/0162269 (2004-08-01), Petrus
patent: 2004/0225077 (2004-11-01), Gravett et al.
patent: 2005/0101563 (2005-05-01), Pulaski et al.
patent: 2005/0215487 (2005-09-01), Holick et al.
patent: 2007/0014832 (2007-01-01), Uhrich
patent: 2007/0020254 (2007-01-01), Levin
patent: 2223051 (1973-12-01), None
patent: 1 320 373 (2007-03-01), None
patent: 1 383 465 (1974-02-01), None
patent: 54-55545 (1979-05-01), None
patent: 54 055545 (1979-05-01), None
patent: WO 91/04013 (1991-04-01), None
patent: WO 99/52528 (1999-10-01), None
patent: WO 01/41753 (2001-06-01), None
patent: WO 01/41753 (2001-06-01), None
patent: WO 01/41783 (2001-06-01), None
patent: WO 02/17890 (2002-03-01), None
patent: WO 02/26239 (2002-04-01), None
patent: WO 02/076423 (2002-10-01), None
patent: WO 03/015797 (2003-02-01), None
patent: WO 03/015799 (2003-02-01), None
patent: WO 03/099013 (2003-12-01), None
patent: WO 2004/002457 (2004-01-01), None
patent: WO 2005/116086 (2005-12-01), None
patent: WO 2005/116086 (2005-12-01), None
patent: WO 2005/116086 (2006-08-01), None
McAlindon et al. JAMA (2000), vol. 283, No. 11, pp. 1469-1475.
Aghazadeh-Habashi et al., “High performance liquid chromatographic determination of N-butyryl glucosamine in rat plasma,” 2005,J. of Chromatography B, 819:91-96.
Aghazadeh-Habashi et al., “Single Dose Pharmacokinetics and Bioavailability of Glucosamine in the Rat,” 2002,J. Pharm. Pharmaceut. Sci., 5(2):181-184.
Akatsu et al., “Comparative Effects of Non-Steroidal Anti-inflammatory Drugs, Mefenamic acid, Metiazinic acid and glucametacin on the inflammatory response induced by subcutaneous implantation of human dental plaque and on the mitotic activity of isoproterenol-stimulated parotid glands of rats,” 1986,Cellular and Molecular Biology, 32(5):619-626.
Albert, “Chemical Aspects of Selective Toxicity,” 1958,Nature, 182(4633):421-423.
Anastassiades et al., “Non-steroidal anti-inflammatory agents in the primary treatment of rheumatoid arthritis,” 1979,Can. Med. Assoc. J., 121(8):1046-1047.
Anderson, et al., “Glucosamine effects in humans: a review of effects on glucose metabolism, side effects, safety considerations and efficacy,” 2005,Food and Chemical Toxicology, 43:187-201.
Andreozzi et al., “Enthalpy relaxation of low molecular weight PMMA: a stragegy to evaluate the Tool-Narayanaswamy-Moynihan model parameters,” 2003,J. Physics: Condensed Matter, 15(11):S1215-S1226.
Bach et al., “Percutaneous penetration enhancement and its quantification,” 1998,Eur. J. Pharm. Biopharm, 46:1-13.
Baker et al., “The Short- and Long-Term Safety of 5-Aminosalicylate Products in the Treatment of Ulcerative Colitis,” 2004,Rev. Gastroenterol. Disord., 4(2):86-91.
Barry, “Lipid-Protein-Partitioning theory of skin penetration enhancement,” 1991,J. Control. Release, 15:237-248.
Benini et al., “In utero exposure to nonsteroidal anti-inflammatory drugs: neonatal renal failure,” 2004,Pediatr. Nephrol., 19(2):232-234.
Bergmann et al., 1932, “Synthesen mit Glucosamin,”Chemische Berichte, 64(5):975-980.
Bernacki et al., 1977, J.Supramolecular Structure, 7:235-250.
Berner et al., “Alcohols” inPercutaneous Penetration Enhancers. Smith, E.W. Maibach, H.I., Eds., CRC Press, Boca Raton, FL., Title page, Copyright page, Table of Contents, and pp. 45-60 (1995).
Bhosale et al., “Preparation and Characterization of Mutual Prodrugs of Ibuprofen,” 2004,Indian J. Pharm. Sci., 66(2):158-163.
Campo et al., “Improved high-performance liquid chromatographic method to estimate aminosugars and its application to glycosaminoglycan determination in plasma and serum,” 2001,J. Chrom. B, 765:151-160.
Capelli et al., “Further Studies on Glucametacin in Rheumatoid Arthritis and in Other Chronic Types of Rheumatism,” 1981,Curr. Med. Res. Opin., 7(4):227-233.
Capomacchia, Anthony C. “UGA-NCAT: Bridges to the Doctorate,” Grant Abstract, Grant No. 1R25GM066321-01 [online]. National Institute of General Medical Sciences, National Institutes of Health, project dates Aug. 6, 2002 to Jul. 31, 2005 [retrieved on May 30, 2007]. Retrieved from the Internet: <http://crisp.cit.nih.gov/crisp/CRISP—LIB.getdoc?textkey=6545266&p—grant—num=1R25GM066321-01&p—query=&ticket=45195245&p—audit—session—id=2630 06114&p—keywords=>; 2 pgs.
Capomacchia, Anthony C. “UGA-NCAT: Bridges to the Doctorate,” Grant Abstract, Grant No. 5R25GM066321-02 [online]. National Institute of General Medical Sciences, National Institutes of Health, project dates Aug. 6, 2002 to Jul. 31, 2005 [retrieved on Sep. 10, 2007]. Retrieved from the Internet: <http://crisp.cit.nih.gov/crisp/CRISP—LIB.getdoc?textkey=6642189&p—grant—num=5R25GM066321-02&p—query=&ticket=45195245&p—audit—session—id=263006114&p—keywords=>; 2 pgs.
Capomacchia, Anthony C. “UGA-NCAT: Bridges to the Doctorate,” Grant Abstract, Grant No. 5R25GM066321-03 [online]. National Institute of General Medical Sciences, National Institutes of Health, project dates Aug. 6, 2002 to Jul. 31, 2006 [retrieved on Sep. 10, 2007]. Retrieved from the Internet: <http://crisp.cit.nih.gov/crisp/CRISP—LIB.getdoc?textkey=6797359&p—grant—num=5R25GM066321-03&p—query=&ticket=45195245&p—audit—session—id=263006114&p—keywords=>; 2 pgs.
Carstens et al., “Double-Blind Comparative Study on the Analgesic and Anti-Inflamatory Activity of Glucamethacin, Aspirin and Placebo in Oral Surgery,”1987,Odont. Chilena, 35:31-39.
Chauviere et al., “Synthesis and Biological Activity of Nitro Heterocycles Analogous to Megazol, a Trypanocidal Lead,” 2003,J. Med. Chem., 46:427-440.
Chemical Market Reporter, “Specialty Supplements are the Bright Spot in
Beach J. Warren
Capomacchia Anthony C.
Garner, Jr. Solomon T.
Lewis Patrick
Mueting Raasch & Gebhardt, P.A.
The University of Georgia Research Foundation Inc.
LandOfFree
Glucosamine and glucosamine/anti-inflammatory mutual... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glucosamine and glucosamine/anti-inflammatory mutual..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glucosamine and glucosamine/anti-inflammatory mutual... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4284459